Published in Graefes Arch Clin Exp Ophthalmol on June 11, 2016
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Evolving guidelines for intravitreous injections. Retina (2004) 3.39
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology (2001) 3.12
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology (2013) 2.40
Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology (2015) 2.20
Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. Am J Ophthalmol (2010) 1.83
Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) (2009) 1.68
Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina (2009) 1.46
RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology (2013) 1.32
Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol (2012) 1.31
Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol (2013) 1.24
Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol (2008) 1.24
Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol (2008) 1.18
Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina (2010) 1.10
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol (2008) 1.10
Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) (2012) 1.07
Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina (2010) 1.05
Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina (2013) 1.02
Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol (2010) 0.99
Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol (2011) 0.98
Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina (2012) 0.98
Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol (2012) 0.93
Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology (2013) 0.92
Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina (2010) 0.92
Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol (2006) 0.87
Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol (2012) 0.83
Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina (2012) 0.83
Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina (2006) 0.82
Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia. Klin Monbl Augenheilkd (2013) 0.79
[Degenerative myopia: recurrence of subretinal neovessels after laser photocoagulation]. J Fr Ophtalmol (1990) 0.77
Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol (2014) 0.77